Advice

in the absence of a submission from the holder of the marketing authorisation:

dasatinib (Sprycel®) is not recommended for use within NHSScotland.

Indication under review: the treatment of paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia in combination with chemotherapy.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland.

Download detailed advice392KB (PDF)

Download

Medicine details

Medicine name:
dasatinib (Sprycel)
SMC ID:
SMC2192
Indication:
The treatment of paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia in combination with chemotherapy.
Pharmaceutical company
Bristol-Myers Squibb Pharmaceuticals Ltd
BNF chapter
Submission type
Non submission
Status
Not recommended
Date advice published:
13 May 2019